A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2023. dec. 1.
- Várható befejezés
- 2026. nov.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Obinutuzumab Injection [Gazyva]
- A regiszteradat frissítve
- 2025. február 24.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children aged 12 to 18 with primary immune thrombocytopenia (ITP), a low platelet count caused by the immune system. Their disease did not respond well to steroid treatment or came back after it. They will receive Obinutuzumab.
- Életkor
- 12 to 18 years
- Nem
- All sexes
- A betegség stádiuma
- Persistent or chronic primary ITP. Platelet count below 30 X 10^9/L, measured at least 2 times during screening, at least 1 week apart, and within 2 days before treatment. ECOG score of 2 or less (able to care for yourself). Heart function class 2 or less. Liver and kidney tests below 1.5 times the upper normal limit.
- Korábbi kezelés
- Steroid (hormone) treatment failed, the disease came back, or the person depends on steroids. Emergency ITP treatment (such as methylprednisolone, platelet transfusion, IVIG) must have ended at least 2 weeks before. Maintenance steroids (0.5mg/kg prednisone or less) or TPO receptor agonists must be at a stable dose for at least 4 weeks. Azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus must be stopped at least 4 weeks before. Rituximab must have ended more than 3 months before. Spleen removal must be more than 6 months before.
A részvétel fő kizáró okai
- Low platelets caused by another disease, such as connective tissue disease, bone marrow failure, cancer, lymphoma, drugs or inherited conditions
- HIV, or active or uncontrolled infections such as hepatitis B, hepatitis C, cytomegalovirus, EB virus or syphilis
- Severe bleeding, such as coughing blood, stomach bleeding or bleeding in the brain
- Any blood clot in veins or arteries, or heart disease needing treatment
- Past solid cancer, stem cell transplant or organ transplant, or taking antiplatelet drugs
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Age 12-18 years old, male or female
- Conform to the diagnostic criteria of persistent or chronic immune Thrombocytopenia (ITP)
- With a platelet count of <30 X 10\^9/L measured within 2 days prior to administration(Platelet counts were measured at least 2 times during screening (at least 1 week apart) with platelets<30 X 10\^9/L)
- Failure or recurrence of previous hormonal therapy or hormone dependence
- The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration
- Signed and dated written informed consent
- With Liver and kidney function<1.5×upper limit of normal, such as ALT、AST,BUN,Cre,etc
- ECOG physical state score ≤ 2 points
- Cardiac function of the New York Society of Cardiac Function ≤ 2
- Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was>3 months;More than 6 months after splenectomy
Ki nem vehet részt
- Patients taking antiplatelet drugs at the same time
- Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases
- Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc
- Subjects infected with human immunodeficiency virus (HIV)
- Uncontrollable or active infections during the screening period, including hepatitis B, hepatitis C, cytomegalovirus, EB virus, or positive syphilis antigen
- Subjects with extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage
- Subjects with heart disease that requires treatment or hypertension that has been judged by researchers to be poorly controlled currently
- Subjects with any venous or arterial thrombosis, atherosclerosis, and other diseases
- Subjects with a history of malignant solid tumor or have received allogeneic stem cell transplantation or organ transplantation
- Subjects with mental disorders who are unable to sign normal informed consent and conduct trials and follow-up
- Subjects with other serious diseases that may limit their participation in this trial (diabetes; severe cardiac insufficiency; myocardial obstruction or unstable arrhythmia or unstable angina pectoris in the last 6 months; gastric ulcer; active autoimmune disease, etc.)
- Subjects with septicemia or other irregular bleeding
- Any medical history or condition that the investigator deems unsuitable for participation in the study
- Subjects whose toxic symptoms caused by pre-trial treatment have not disappeared
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 12 és 18 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.
A vizsgálat csoportja
- Intervention (Obinutuzumab)A vizsgált kezelés
60 enrolled subjects: one infusion
Kezelés: Obinutuzumab Injection [Gazyva]
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-Human CD20 Monoclonal Antibody Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06094881: ki vehet részt
- A regiszteradat frissítve
- 2025. február 24.